High Yield vs. Sustainable Growth: Why AbbVie's Dividend Beats Pfizer's Despite the Lower Payout

AbbVie and Pfizer reported fourth-quarter earnings in early February, with the reports depicting two very different company stories. The divergence suggests potential stock-specific moves and increased volatility in the healthcare sector rather than a broad market impact; portfolio managers should focus on company fundamentals and guidance for position adjustments.

Analysis

AbbVie and Pfizer reported fourth-quarter earnings in early February, with the reports depicting two very different company stories. The divergence suggests potential stock-specific moves and increased volatility in the healthcare sector rather than a broad market impact; portfolio managers should focus on company fundamentals and guidance for position adjustments.